Skip to content

Study · Measured the body's own peptide · 1985

3 results

Intestinal lymphangiectasia and thymic hypoplasia.

Sorensen RU, Halpin TC, Abramowsky CR, Hornick DL, Miller KM, Naylor P, Incefy GS

Clinical and experimental immunology1 Jan 1985Cited by 12 (Europe PMC)

PMID3971596 (opens in a new tab)PepBankPUB-03971596
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelCase report or seriesOther

    In a child with intestinal lymphangiectasia and thymic deficiency, serum thymosin alpha‑1 was absent or decreased.

    In plain wordsIn one child with intestinal lymphangiectasia, the body's own thymosin alpha‑1 was absent or low in serum.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum thymosin alpha 1 in a patient with lymphangiectasia
    Study

    n = 1

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    an absence or decrease of the serum thymic factor (thymulin) and thymosin alpha 1.
    1 context sentence
    Summary · context
    We have evaluated the immunological abnormalities present in a 6 year old patient with primary intestinal and generalized lymphangiectasia confirmed by intestinal, lung and lymph node biopsies.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

Studies that did not test the peptide alone2

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 02HumanNot a test of Thymosin alpha-1 aloneCase report or seriesEfficacy outcome

    In a child with intestinal lymphangiectasia, daily thymosin fraction 5 gave a transient clinical improvement that was not sustained on a weekly schedule.

    In plain wordsIn one child, a thymus extract mixture gave a short clinical improvement that did not last on a weekly schedule.

    Peptide
    Thymosin alpha-1
    Outcome
    MixedClinical response to thymosin fraction 5
    Study

    n = 1

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Daily treatment with this preparation resulted in a transient clinical improvement which could not be sustained on a weekly thymosin treatment schedule.
    2 context sentences
    Summary · context
    In an attempt to increase T lymphocyte development, the patient was treated with thymosin fraction 5.
    Summary · context
    We have evaluated the immunological abnormalities present in a 6 year old patient with primary intestinal and generalized lymphangiectasia confirmed by intestinal, lung and lymph node biopsies.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 03HumanNot a test of Thymosin alpha-1 aloneCase report or seriesEfficacy outcome

    In a child with intestinal lymphangiectasia, lymphocyte numbers did not increase during thymosin fraction 5 treatment.

    In plain wordsIn one child, lymphocyte numbers did not rise during treatment with a thymus extract mixture.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeLymphocyte numbers during thymosin fraction 5
    Study

    n = 1

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    However, lymphocyte numbers did not increase during this treatment.
    2 context sentences
    Summary · context
    In an attempt to increase T lymphocyte development, the patient was treated with thymosin fraction 5.
    Summary · context
    We have evaluated the immunological abnormalities present in a 6 year old patient with primary intestinal and generalized lymphangiectasia confirmed by intestinal, lung and lymph node biopsies.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    21 Oct 2026, 12:50 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    10 Oct 2026, 08:55 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.